Pioglitazone together with imatinib in chronic myeloid leukemia: A proof of concept study

Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population

(2016) Hannah Bower et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular monitoring of chronic myeloid leukemia: principles and interlaboratory standardization

(2015) Nicholas C. P. Cross et al.   ANNALS OF HEMATOLOGY

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes

(2015) James D. Lewis et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

(2015) L Kalmanti et al.   LEUKEMIA

Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists

(2015) Stéphane Prost et al.   NATURE

JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo

(2014) P. Gallipoli et al.   BLOOD

Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis

(2014) Daniel Levin et al.   DIABETOLOGIA

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha

(2013) Rabab M. El Eit et al.   INTERNATIONAL JOURNAL OF CANCER

Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

(2013) Philippe Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML

(2012) Florian H. Heidel et al.   Cell Stem Cell

Standardized definitions of molecular response in chronic myeloid leukemia

(2012) N C P Cross et al.   LEUKEMIA

The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

(2012) L. Azoulay et al.   BMJ-British Medical Journal

Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

(2011) B. Simonsson et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study

(2011) J. D. Lewis et al.   DIABETES CARE

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

(2010) Claude Preudhomme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic Myeloid Leukemia: A Historical Perspective

(2010) John M. Goldman   SEMINARS IN HEMATOLOGY

Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation

(2008) Rihab Nasr et al.   NATURE MEDICINE